Bioventus (BVS) Receivables (2020 - 2026)
Bioventus filings provide 6 years of Receivables readings, the most recent being $131.4 million for Q4 2025.
- On a quarterly basis, Receivables rose 3.07% to $131.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.4 million, a 3.07% increase, with the full-year FY2025 number at $131.4 million, up 3.07% from a year prior.
- Receivables hit $131.4 million in Q4 2025 for Bioventus, up from $130.4 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $155.4 million in Q4 2021 to a low of $89.5 million in Q2 2021.
- Median Receivables over the past 5 years was $127.4 million (2023), compared with a mean of $126.9 million.
- Biggest five-year swings in Receivables: skyrocketed 40.17% in 2022 and later fell 18.21% in 2023.
- Bioventus' Receivables stood at $125.0 million in 2021, then grew by 9.21% to $136.6 million in 2022, then fell by 6.81% to $127.3 million in 2023, then grew by 0.16% to $127.5 million in 2024, then grew by 3.07% to $131.4 million in 2025.
- The last three reported values for Receivables were $131.4 million (Q4 2025), $130.4 million (Q3 2025), and $135.3 million (Q2 2025) per Business Quant data.